Lonquex Dosage/Direction for Use

Lonquex treatment should be initiated and supervised by physicians experienced in oncology or haematology.
Posology: One 6 mg dose of lipegfilgrastim (a single pre-filled syringe of Lonquex) is recommended for each chemotherapy cycle, given approximately 24 hours after cytotoxic chemotherapy.
Special populations: Elderly patients: In clinical studies with a limited number of elderly patients, there was no relevant age-related difference with regard to the efficacy or safety profiles of lipegfilgrastim. Therefore, no adjustment of the dose is necessary for elderly patients.
Patients with renal impairment: Currently available data are described in Pharmacology: Pharmacokinetics under Actions, but no recommendation on a posology can be made.
Patients with hepatic impairment: Currently available data are described in Pharmacology: Pharmacokinetics under Actions, but no recommendation on a posology can be made.
Paediatric population: The safety and efficacy of Lonquex in children and adolescents aged up to 17 years have not yet been established. Currently available data are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions.
Method of administration: The solution is injected subcutaneously (SC). The injections should be given into the abdomen, upper arm or thigh.
Self-administration of Lonquex should only be performed by patients who are well motivated, adequately trained and have access to expert advice. The first injection should be performed under direct medical supervision.
For instructions on handling of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.